88.01
+5.07
+(6.11%)
At close: January 24 at 3:55:58 PM EST
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | 18.62 | -- |
Revenue Estimate
| Currency in DKK | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 12 | 3 | 22 | 22 |
| Avg. Estimate | 83.03B | 79.73B | 287.76B | 347.26B |
| Low Estimate | 83.03B | 78.53B | 287.76B | 346.97B |
| High Estimate | 83.03B | 80.55B | 289.67B | 364.93B |
| Year Ago Sales | 65.86B | 65.35B | 232.26B | 287.76B |
| Sales Growth (year/est) | 26.06% | 22.01% | 23.89% | 20.68% |
EPS Trend
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | 1 | 1 |
| Up Last 30 Days | -- | -- | 1 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| NONOF | -- | -- | -- | -- |
| S&P 500 | 9.90% | 11.00% | 14.01% | 13.54% |
Related Tickers
LLY Eli Lilly and Company
785.41
+2.45%
AMGN Amgen Inc.
275.42
-0.89%
AZN AstraZeneca PLC
69.06
+0.67%
NVS Novartis AG
99.97
-0.06%
AZNCF AstraZeneca PLC
137.95
-0.78%
JNJ Johnson & Johnson
146.82
+0.12%
MRK Merck & Co., Inc.
95.55
-1.12%
SNY Sanofi
52.48
+0.96%
ABBV AbbVie Inc.
170.30
-0.22%
GSK GSK plc
34.27
+0.65%